BI 655088

Drug Profile

BI 655088

Alternative Names: Anti-CX3CR1 Nanobody®; BI655088

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Boehringer Ingelheim
  • Class Proteins
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Kidney disorders

Most Recent Events

  • 19 Jun 2018 Ablynx has been acquired by Sanofi
  • 31 May 2016 Boehringer Ingelheim suspends enrolment in a phase I trial in Healthy volunteers in Belgium (NCT02696616)
  • 21 Apr 2016 Phase-I clinical trials in Kidney disorders (In volunteers) in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top